Benzinga All Access

Ken Londoner, CEO of BioSig Technologies (NASDAQ: BSGM), was recently a guest on Benzinga’s All-Access BioSig is a digital signal processing company that has created the PURE EP Platform. The company unites expertise in medical engineering, intellectual property and workflow to deliver...

Isaac Dietrich, CFO of Greenwave Technology Solutions, Inc. (NASDAQ: GWAV), was recently interviewed by Benzinga. Greenwave Technology Solutions, Inc., through its wholly owned subsidiary Empire Services, Inc., is a leading operator of 11 metal recycling facilities in Virginia and North Carolina....

Randy Milby, CEO of Hillstream BioPharma (NASDAQ: HILS), was a guest on Benzinga’s All-Access. Hillstream BioPharma is a biotechnology company developing a focused portfolio of therapeutic candidates targeting drug-resistant and devastating cancers. The company’s emerging immuno-...

Samir Tabar, CEO of Bit Digital (NASDAQ: BTBT), was a guest on Benzinga’s All-Access. Bit Digital is a large scale Bitcoin (CRYPTO: BTC) mining company with a strategic focus on sustainability. The majority of its operations run, on average, on carbon-free energy sources, making it a leader...

Marc Hedrick, President & CEO of Plus Therapeutics (NASDAQ: PSTV), was a guest on Benzinga’s All-Access. Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics with the potential to enhance clinical outcomes in patients with difficult-to-treat...

Andrew Fox, Founder, Chairman & CEO of Charge Enterprises, Inc. (NASDAQ: CRGE) was recently a guest on Benzinga’s All-Access. Charge Enterprises is an infrastructure and technology company that is enabling the next wave of transportation and connectivity by building, designing and...

Paul Galvin, Chairman & CEO of Safe & Green Holdings (NASDAQ: SGBX), was recently a guest on Benzinga’s All-Access. Safe & Green is a modular solutions company that has created industry-leading processes to design, manufacture and install modular homes, medical facilities and...

Brett H. Pojunis, CEO of GPO Plus, Inc. (OTCMKTS: GPOX), was recently a guest on Benzinga’s All-Access. GPO Plus is a product development, manufacturing and distribution company which offers a diverse portfolio of high-quality innovative products sold directly to consumers and retailers. The...

Frank Bedu-Addo, Ph.D., CEO & Director of PDS Biotechnology (NASDAQ: PDSB), was recently a guest on Benzinga’s All-Access. PDS Biotech is a clinical stage biopharmaceutical company with a growing pipeline of cancer immunotherapies and infectious disease vaccines. The company’s...

Chris Loeffler, CEO of CaliberCos, Inc. (NASDAQ: CWD), was recently a guest on Benzinga’s All-Access. Caliber is a vertically integrated asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company creates,...

Rodney Varner, CEO, Chairman & President of Genprex, Inc. (NASDAQ: GNPX), was recently a guest on Benzinga’s All-Access. Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are...

Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access. Actinium is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision...

Greg Gorgas, President & CEO of Artelo Biosciences (NASDAQ: ARTL), was recently a guest on Benzinga’s All-Access. Artelo is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways...

Dennis Phares, CEO, and John Marchetti, CFO of Dragonfly Energy (NASDAQ: DFLI) were recently guests on Benzinga’s All-Access. Dragonfly is a lithium ion battery technology company that focuses on the manufacturing of the cells themselves. The company has developed an innovative dry powder...

Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical stage neuroscience company developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company’s technology “selectively modulates” a central cellular damage...